Consistently, it was previously reported that chemical inhibition of Gln transporter ASCT2 results in inhibition of tumor growth and metastatic spread in xenograft prostate tumor models 70, and that high blood levels of Gln, which is derived from tumor stroma, are associated with resistance to androgen deprivation therapy in PCa patients 71. Here, SLC1A5 is linked to neoplasm.